Free Trial
NYSE:LLY

Eli Lilly and Company (LLY) Stock Price, News & Analysis

Eli Lilly and Company logo
$819.88 -4.18 (-0.51%)
As of 12:03 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Eli Lilly and Company Stock (NYSE:LLY)

Key Stats

Today's Range
$813.26
$834.65
50-Day Range
$726.24
$930.22
52-Week Range
$711.40
$972.53
Volume
1.21 million shs
Average Volume
3.12 million shs
Market Capitalization
$777.38 billion
P/E Ratio
70.09
Dividend Yield
0.73%
Price Target
$1,009.72
Consensus Rating
Moderate Buy

Company Overview

Eli Lilly and Company is a US-based multinational pharmaceutical company. It is the 12th largest pharmaceutical company by revenue and has offices in 16 countries. Its medicines are sold in at least 125 countries including its 8 blockbuster drugs. The company is a member of the S&P 500 and S&P 100 indices, it brought in roughly $5.5 billion in revenue for 2021 and employs more than 35,000 people across its network of research and production facilities.

Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly. The colonel, a veteran of the Civil War, had recently dissolved an unsatisfactory partnership and set on his own to produce and develop medicinal chemicals. Colonel Lilly remained as president until his death in 1898. His charge to his family, company and coworkers was to “take what you find here and make it better and better”. The company is well-known for many drugs, including the first mass-marketing of quinine to treat malaria.

The company brought in $4,470 in its first year and saw that figure grow 10X over the next 3. Among the many innovations during this time period is the addition of gelation coatings for pills which helped set the company up for rapid expansion. The company was incorporated in 1881 as Eli Lilly and Company issuing stock to family and friends. The 1900s brought about more change for the company, change in the form of expansion which included international markets.

Advancements during the war years included increases in efficiency due to increased automation and the development of precision technologies. Among the technologies was pill manufacturing which included injecting medicines directly into a gelation capsule. This method allowed for more exact dosing, setting the standard for modern production. The company produced capsules for itself and sold excess capacity to competitors. Other major advancements include fruit flavorings in medicine, straight-line manufacturing and a method of blueprinting manufacturing tickets to prevent errors.

The modern period saw the company grow and discover new, world-class pharmaceuticals. Today, the company is engaged in the discovery, development and marketing of human pharmaceuticals. It offers a wide range of treatments, including Prozac but is perhaps most noteworthy for its work with insulin. The company is the first to mass produce insulin and has made numerous advances in treating diabetes in the time since. While other drugs are more widely known, its diabetic drugs Basaglar, Jardience, Trulicity, Humalog and Humulin are its top-sellers and contribute the bulk of revenue and cash flow.

Along with Diabetic research, the company also focuses on Alzheimer's, Oncology, Immunology, Obesity and Pain care. At the end of 2022, the company pipeline had 23 compounds in Phase 3 clinical trials and 1 in review. There were another 18 in Phase 2 trials and more than 2 dozen in Phase 1 trials. The average cost to discover a new drug was running at $2.6 billion with a 10-year discovery-to-patient timeline.

Remove Ads

Eli Lilly and Company Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
90th Percentile Overall Score

LLY MarketRank™: 

Eli Lilly and Company scored higher than 90% of companies evaluated by MarketBeat, and ranked 85th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Eli Lilly and Company has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 17 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Eli Lilly and Company has only been the subject of 3 research reports in the past 90 days.

  • Read more about Eli Lilly and Company's stock forecast and price target.
  • Earnings Growth

    Earnings for Eli Lilly and Company are expected to grow by 32.54% in the coming year, from $23.48 to $31.12 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Eli Lilly and Company is 70.25, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.34.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Eli Lilly and Company is 70.25, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 23.77.

  • Price to Earnings Growth Ratio

    Eli Lilly and Company has a PEG Ratio of 1.40. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Eli Lilly and Company has a P/B Ratio of 54.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Eli Lilly and Company's valuation and earnings.
  • Percentage of Shares Shorted

    0.85% of the float of Eli Lilly and Company has been sold short.
  • Short Interest Ratio / Days to Cover

    Eli Lilly and Company has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Eli Lilly and Company has recently increased by 2.26%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Eli Lilly and Company has a dividend yield of 0.69%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Eli Lilly and Company has been increasing its dividend for 11 years.

  • Dividend Coverage

    The dividend payout ratio of Eli Lilly and Company is 51.24%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Eli Lilly and Company will have a dividend payout ratio of 19.28% next year. This indicates that Eli Lilly and Company will be able to sustain or increase its dividend.

  • Read more about Eli Lilly and Company's dividend.
  • Percentage of Shares Shorted

    0.85% of the float of Eli Lilly and Company has been sold short.
  • Short Interest Ratio / Days to Cover

    Eli Lilly and Company has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Eli Lilly and Company has recently increased by 2.26%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Eli Lilly and Company has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 150 news articles for Eli Lilly and Company this week, compared to 65 articles on an average week.
  • Search Interest

    Only 110 people have searched for LLY on MarketBeat in the last 30 days. This is a decrease of -54% compared to the previous 30 days.
  • MarketBeat Follows

    Only 89 people have added Eli Lilly and Company to their MarketBeat watchlist in the last 30 days. This is a decrease of -32% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Eli Lilly and Company insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.13% of the stock of Eli Lilly and Company is held by insiders.

  • Percentage Held by Institutions

    82.53% of the stock of Eli Lilly and Company is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Eli Lilly and Company's insider trading history.
Receive LLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eli Lilly and Company and its competitors with MarketBeat's FREE daily newsletter.

LLY Stock News Headlines

Novo Nordisk sogn
Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors (LLY)
Novo Nordisk slashed prices on its GLP-1 obesity drugs as it launches NovoCare to gain compounded GLP-1 users as the compounding labs face deadlines to cease.
Financial markets news icon
MarketBeat Week in Review – 03/03 - 03/07 (LLY)
Stocks had another down week despite a mostly benign jobs report; and with the latest reads on inflation coming next week the uncertainty may continue
Former CIA to Trump – Will you Shut down this secret lab?
Deep in the sands of New Mexico lies a government lab so secret it makes Area 51 look like a tourist spot… The scientists here aren’t toying with viruses or weather manipulation technology… No, they’re into something far more alien…
Indianapolis - Circa June 2017: Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals XI - Stock Editorial Photography
Eli Lilly Pours $27B Into U.S. Growth—What It Means for Investors
Pharma giant Eli Lilly announced plans to make a massive investment in the United States. What does this and another big announcement mean for Lilly?
Donna Cooper holds up a dosage of Wegovy, a drug used for weight loss, at her home in Front Royal, …
Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker Eli Lilly
Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance
See More Headlines

LLY Stock Analysis - Frequently Asked Questions

Eli Lilly and Company's stock was trading at $772.00 on January 1st, 2025. Since then, LLY stock has increased by 6.4% and is now trading at $821.68.
View the best growth stocks for 2025 here
.

Eli Lilly and Company (NYSE:LLY) announced its quarterly earnings data on Thursday, February, 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by $0.13. Eli Lilly and Company had a trailing twelve-month return on equity of 85.24% and a net margin of 23.51%.
Read the conference call transcript
.

Eli Lilly and Company's Board of Directors initiated a stock buyback plan on Monday, December 9th 2024, which permits the company to buy back $15,000,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 2% of its shares through open market purchases. Shares buyback plans are often a sign that the company's management believes its shares are undervalued.

The following companies are subsidiaries of Eli Lilly and Company: Protomer Technologies, Prevail Therapeutics Inc., Disarm Therapeutics, Disarm Therapeutics, Dermira, Loxo Oncology, CoLucid Pharmaceuticals, and others.

Top institutional investors of Eli Lilly and Company include Vanguard Group Inc. (7.82%), PNC Financial Services Group Inc. (5.40%), FMR LLC (3.22%) and Price T Rowe Associates Inc. MD (2.20%). Insiders that own company stock include Lilly Endowment Inc, Jackson P Tai, Anne E White, Patrik Jonsson, Johna Norton, Alonzo Weems, Donald A Zakrowski and Acquisition Corp Kearny.
View institutional ownership trends
.

Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eli Lilly and Company investors own include Broadcom (AVGO), NVIDIA (NVDA), Meta Platforms (META), BlackRock (BLK), Salesforce (CRM), Chevron (CVX) and ServiceNow (NOW).

Company Calendar

Last Earnings
2/06/2025
Ex-Dividend for 3/10 Dividend
2/14/2025
Dividend Payable
3/10/2025
Today
3/12/2025
Next Earnings (Estimated)
4/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NYSE:LLY
Employees
39,000
Year Founded
1876

Price Target and Rating

Average Stock Price Target
$1,009.72
High Stock Price Target
$1,190.00
Low Stock Price Target
$723.00
Potential Upside/Downside
+21.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.85
Research Coverage
20 Analysts

Profitability

Trailing P/E Ratio
70.56
Forward P/E Ratio
35.27
P/E Growth
1.4
Net Income
$10.59 billion
Pretax Margin
28.15%

Debt

Sales & Book Value

Annual Sales
$45.04 billion
Cash Flow
$13.50 per share
Price / Cash Flow
61.34
Book Value
$15.05 per share
Price / Book
55.02

Miscellaneous

Free Float
948,082,000
Market Cap
$785.14 billion
Optionable
Optionable
Beta
0.34

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NYSE:LLY) was last updated on 3/12/2025 by MarketBeat.com Staff
From Our Partners